Medical network - on November 30, the titled "from the world's bestselling medicines and research and development status of the Chinese pharmaceutical market supply and end demand change" report, the CFDA south m Intranet by general manager/chief researcher Zhang Buyong mainly talked about the content includes: 2016 in the first half of the world's best-selling drug situation, the global and domestic development present situation, the end demand change and development trend in the future.
Global status top-selling drugs: biological medicine has been developing rapidly, anti-tumor is still the key direction
Zhang Buyong first introduced in 2016 in the first half of global drug sales done in products. Look from drug type, chemical medicine, though 53%, but gradually decreased; In recent years, biological medicine has been developing rapidly, the large molecules such as bio-pharmaceutical products ratio has risen to 47%, segment type, single drug resistance 17%, fusion protein drugs, hormone analogs, and other types of biological medicine accounted for 10%.
TOP100 varieties most top five company Johnson & Johnson, Merck and Pfizer and novartis and roche. Zhang Buyong mentioned, TOP100 varieties most top five treatment categories, antitumor remained in the first place, followed by diabetes, HIV infection, autoimmune disease, and multiple sclerosis.
Much attention has been paid to global research and development: cancer; Domestic research and development: for his single resistance class will gradually localization in the future
As of September 18, 2015, the global total of more than 20000 drugs in development that Zhang Buyong mentioned that "72% of the more than 20000 varieties in development, at the preclinical stage, Ⅲ clinical and new drug application stage of aggregate is 6%, it can be seen that at present each big, medium-sized companies are lack of international advanced clinical projects." This and more than 20000 products in the research, there are indications do statistical product has more than 8000, and accounted for most of the cancer is still, at 50%, that is in keeping with the present situation of the best-selling products around the world, anti-tumor is still the most popular field.
Till the end of December, 2014 CFDA has approved 16738 varieties of medicines, approval number in more than 50 drugs 610, accounts for only 3.64% of all drug varieties, although it accounts for 56.44% of the total approval number, the approval document for the registration of the same drug varieties too much repetition.
Zhang Buyong mentioned "low level repeated serious at present domestic stock products, quality is uneven, so the status quo of further promoting the CFDA consistency evaluation work, to supply good products to screen out." Domestic research and development status quo is for single kind of high-profile resistance, the future will gradually achieve localization, the situation for the common people, can get more cost-effective therapeutic drugs. ", there are 92 manufacturers declaration for 16, the next 3 to 5 years for, there will be a lot of product on the market."
Three terminal six major markets: demand continues to increase, the development tend to be more standardized
Zhang Buyong, said China's drug supply is currently in the transformation and upgrading, mass transfer efficiency of phase, and the demand of the terminal is huge. Three terminal six big market in China in 2015 the total sales of 1.3829 trillion yuan, if join not statistics "private hospitals and private clinics, village clinic", in 2015 China pharmaceutical total sales of more than 1.6 trillion yuan, accounting for 2015 40% of China's total health expenses of about 4 trillion yuan. "Demand is big, but the structure is not reasonable." Zhang Buyong mentioned, "at present, China's market products most of the top 20 drugs such as antibiotics, sodium chloride, and the most popular products such as anti-tumor, diabetes therapeutic drugs."
Trend for the future of the three terminals, Zhang Buyong said that public hospital terminal will tend to standardization, rationalization and legalization, the future direction of development includes three parts, the original product will be replaced by through consistency evaluation of generics gradually; High price product will be replaced by high sexual price products gradually; Patent innovation medicine/export/exclusive varieties overall good, positive category has a slow disease medicine, the medicine of a serious illness and the children's medicine.
Retail pharmacies terminal will tend to be more professional, great health, Internet, development strategy can lock in the product extension strategy, big health strategy and Internet strategy. Public primary care terminal will tend to cost, standardization, refinement, the future development direction, including high price product will be replaced by high sexual price products gradually; Overall good exclusive varieties.
M Intranet after last year's successful launch of Chinese public medical institutions and drug eight pattern database, in this year's session of the national pharmaceutical 28 grand economic information release issued "China retail pharmacy drug terminal competition pattern library". The library by the China urban retail pharmacy drug terminal competition (national city bigger version) "and" key cities for the retail pharmacies and drug terminal competition (22 cities larger version) ", which is divided into retail pharmacies chemical medicines and proprietary Chinese medicine terminal competitive landscape. , 2017 m network will introduce health care products, medical apparatus and instruments, Chinese medicine yinpian retail pharmacies terminal competition pattern library, stay tuned. (m Intranet Liu Qi mei) |
